Sartorius AGSARTF -1.83%85 PB Ratio is 4.22 as of Jun. 24, 2026, which is 59% below its 10-year median of 10.31. GuruFocus rates SARTF with a GF Score™ of 85/100 and a GF Value™ of $226.12 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 787 Medical Devices & Instruments companies, Sartorius AG ranks worse than 77.76% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-06-24), Sartorius AG's share price is $192.43. Sartorius AG's Book Value per Share for the quarter that ended in Mar. 2026 was $45.65. Hence, Sartorius AG's PB Ratio of today is 4.22.
The historical rank and industry rank for Sartorius AG's PB Ratio or its related term are showing as below:
SARTF'
s PB Ratio Range Over the Past 10 Years
Min: 3.86 Med: 10.31 Max: 43.63
Current: 4.37
During the past 13 years, Sartorius AG's highest PB Ratio was 43.63. The lowest was 3.86. And the median was 10.31.
SARTF's PB Ratio is ranked worse than 77.76% of 787
companies
in the Medical Devices & Instruments industry
Industry Median: 2.04
vs SARTF: 4.37
During the past 12 months, Sartorius AG's average Book Value Per Share Growth Rate was 0.60% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 10.50% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 22.70% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 20.50% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Sartorius AG was 34.90% per year. The lowest was -1.60% per year. And the median was 15.60% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Sartorius AG PB Ratio Related Terms
Sartorius AG PB Ratio Historical Data
* Premium members only.
The historical data trend for Sartorius AG's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Sartorius AG's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sartorius AG PB Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Sartorius AG's PB Ratio distribution charts can be found below:
* The bar in red indicates where Sartorius AG's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Sartorius AG's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Sartorius AG (SARTF) has a PB Ratio of 4.22 as of Jun. 24, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Sartorius AG and its competitors. This is 59% below median its historical median of 10.31. Over the past decade, Sartorius AG's PB Ratio has ranged from 3.86 to 43.63. According to the industry distribution chart, Sartorius AG ranks #612 out of 787 companies in the Medical Devices & Instruments industry, placing it in the top 77.8%.
Is Sartorius AG's PB Ratio too high?
Sartorius AG's current PB Ratio of 4.22 is 59% below median its 10-year median of 10.31. Over the past 10 years, this metric has ranged from a low of 3.86 to a high of 43.63. The Medical Devices & Instruments industry median PB Ratio is 2.04. Sartorius AG's value of 4.22 is 106.9% above this industry median. Based on the distribution chart, Sartorius AG ranks #612 out of 787 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Sartorius AG has a GF Score™ of 85/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sartorius AG's PB Ratio compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Sartorius AG ranks #612 out of 787 companies for PB Ratio. This places Sartorius AG in the lower half of its industry. The industry median PB Ratio is 2.04. Sartorius AG's value of 4.22 is 106.9% above this benchmark. Historically, Sartorius AG's own PB Ratio has ranged from 3.86 to 43.63 over the past decade. While the company's 10-year median is 10.31 vs. the industry median of 2.04, Sartorius AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Medical Devices & Instruments company?
The median PB Ratio among Medical Devices & Instruments companies is 2.04, based on 787 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sartorius AG's current PB Ratio of 4.22 is 106.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Sartorius AG and its competitors. For the Medical Devices & Instruments industry, the median PB Ratio is 2.04 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sartorius AG's current PB Ratio is 4.22, which is 59% below median its own 10-year median of 10.31. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sartorius AG stock overvalued right now?
Based on GuruFocus' analysis, Sartorius AG (SARTF) is currently considered Modestly Undervalued. The stock's GF Value™ is $226.12, compared to a current price of $192.43 — trading 14.9% below its estimated fair value. The current PB Ratio is 4.22, which is 59% below median its 10-year median of 10.31 and 106.9% above the Medical Devices & Instruments industry median of 2.04. Sartorius AG's overall GF Score™ is 85/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Sartorius AG (SARTF), the current PB Ratio is 4.22 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sartorius AG (SARTF) Overvalued in 2026?
Based on GuruFocus' analysis, Sartorius AG stock appears to be undervalued.
The current stock price of $192.43 is trading 14.9% below its estimated GF Value™ of $226.12.
GuruFocus considers Sartorius AG to be Modestly Undervalued.
Key valuation signals for SARTF:
PB Ratio: 4.22 (59% below median its 10-year median of 10.31)
GF Value™: $226.12 vs. price of $192.43 (14.9% below fair value)
Industry Position: 106.9% above the Medical Devices & Instruments median (#612 of 787)
No single metric tells the full story. See the SARTF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sartorius AG is a leading provider of bioprocessing solutions. Its bioprocess division sells equipment and consumables for upstream and downstream manufacturing of biologic drugs and focuses on single-use technology. Its laboratory products and services division offers a wide range of products for laboratory use, including scales, pipettes, and filtration equipment. As of 2024, the bioprocess and LPS divisions contributed 80% and 20% of revenue, respectively. Bioprocess is housed in its subsidiary Sartorius Stedim Biotech, of which Sartorius AG has a 72% ownership and 83% voting control. The business is geographically diverse, with revenue across Europe, Middle East, and Africa (41% of 2024 sales), the Americas (36%), and Asia-Pacific (23%). We estimate China revenue to be around 10%.
85GF Score
Get the complete analysis for SARTF
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SARTF has been successfully added to your 
